Rosemont Pharmaceuticals is the UK’s leading liquid pharmaceuticals business. Its portfolio of oral liquid medicines includes licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.
The Inflexion difference
With substantial experience in successfully executing carve-outs, we have drawn upon our healthcare expertise to establish Rosemont as a standalone business, including using our digital experience to assist with the IT carve-out and invest further in innovation and new product development. We are working with Rosemont to achieve its M&A ambitions by sourcing and evaluating potential targets that complement Rosemont’s current product portfolio.
We’re extremely pleased to be able to announce this exciting new chapter for Rosemont. As a very well established and respected supplier in the industry, we look forward to working with Inflexion and drawing on their relevant experience in our sector to continue to invest in the business and expand our quality product range.
CEO, Rosemont Pharmaceuticals